(Q24649115)

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin--a preliminary report

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Prostanoid therapy for pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Fibrosis regression induced by intravenous gammaglobulin treatment

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Survival with first-line bosentan in patients with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Sildenafil for pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021

Long-term outcomes of scleroderma renal crisis

1 reference

https://api.crossref.org/works/10.1080%2F17402520500233437

7 January 2021